About SPRAVATO® SMDD
The first and only NMDA receptor antagonist approved for 2 subtypes of MDD in adult patients1
SPRAVATO® hypothesized mechanism of action (MOA)
UNMET NEED IN MDSI
17.6 million adults are estimated to have MDD in the US.5
11.5% of these patients have active suicidal ideation with intent.5
These patients need timely attention, but a newly administered oral antidepressant may take 4 to 6 weeks to reach full effect.6
SPRAVATO® clinical program overview
Studied in 449 adult patients with moderate to severe MDD who had active suicidal ideation with intent, across all studies
BASELINE PATIENT CHARACTERISTICS1
Patients included in MDSI trials had active suicidal ideation or behavior that was characterized by the following:
• Thinking (even momentarily) about harming or hurting or injuring oneself
• Having awareness that they might die as a result of self-harm
• Intend to act on thoughts of killing oneself
Patients had a mean MADRS score of 40
Patients reported active, acute suicidal ideation within 24 hours prior to their first dose of study medication
MADRS=Montgomery-Åsberg Depression Rating Scale.
• Patients in both arms received comprehensive standard-of-care (SOC) treatment, including an initial inpatient psychiatric hospitalization and a newly initiated or optimized oral antidepressant (AD) therapy (AD monotherapy or AD plus augmentation) as determined by the investigator
Meet 3 adult patients with MDD in need of timely attention who may be appropriate for SPRAVATO® therapy*
SPRAVATO® therapy for appropriate adult patients with MDD in need of timely attention should only begin after a full evaluation and discussion with a healthcare provider.
*Not actual patients.
1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. July 2020.
2. Uher R, et al. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety. 2014;31:459-471.
3. Grunebaum MF, et al. Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression. Neuropsychopharmacology. 2012;37:697-706.
4. Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer and Adherence. 2012;6:369-388.
5. Data on file. Janssen Pharmaceuticals, Inc. Titusville, NJ.
6. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2010:1-152.